Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy

Non-small Cell Lung Cancer Clinical Trial

Official title:

Open-label Multicenter Multiple Ascending Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Gemcitabine + Cisplatin Chemotherapy (Second Line for Patients With Non-small Cell Lung Cancer) or Paclitaxel + Carboplatin Chemotherapy (Second Line for Patients With Non-small-cell Lung Cancer, Second and Subsequent Lines for Patients With Epithelial Ovarian Cancer)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02728492
• Other study ID #: ONC-13-NSCLC/OVA-7-QUI-1B
• Status: Completed
• Phase: Phase 1
• First received: November 13, 2015
• Last updated: May 2, 2016
• Start date: August 2013
• Est. completion date: January 2016

Study information

• Verified date: May 2016
• Source: NewVac LLC
• Contact: n/a
• Is FDA regulated: No
• Health authority: Russia: Ministry of Health of the Russian Federation
• Study type: Interventional

Clinical Trial Summary

Quisinostat besides its own efficacy, which can potentially lead to better results of polychemotherapy and increase the mean time to progression, it may be demonstrated that Quisinostat leads to sustained tumor sensitivity to platinum drugs. In this study safety and tolerability of multiple administrations of Quisinostat in doses ranging from 8 mg to 12 mg combined with standard backbone chemotherapy in patients with non-small cell lung cancer (second line) and ovarian cancer (second and subsequent lines) will be investigated.

Description:

It was proven that Quisinostat increases HDAC1-inhibited E-cadherin expression (at the low concentrations of 30 nM) which increases susceptibility to epidermal growth factor inhibitors in case of non-small-cell lung cancer and stops proliferation of paclitaxel-resistant cells. Thus, besides its own efficacy, which can potentially lead to better results of polychemotherapy and increase the mean time to progression, it may be demonstrated that Quisinostat leads to sustained tumor sensitivity to platinum drugs and possibly to resensitiztion in case of acquired or primary resistance.

The main objective of the study is to evaluate the safety and tolerability of Quisinostat in multiple ascending doses and establish its maximum tolerated dose (MTD), administered in combination with standard backbone chemotherapy, as follows: Gemcitabine + Cisplatin in patients with non-small-cell lung cancer (second line) and Paclitaxel + Carboplatin in patients with non-small-cell lung cancer (second line) and in patients with ovarian cancer (second and subsequent lines). MTD is defined as maximum dose at which DLT occurs in no more than 1 patient of 6.

Secondary objectives are:

• Study of pharmacokinetics (PK) of multiple dosing of Quisinostat administered in combination with chemotherapy, as follows: Gemcitabine + Cisplatin in patients with non-small-cell lung cancer (second line) and Paclitaxel + Carboplatin in patients with non-small-cell lung cancer (second line) and in patients with ovarian cancer (second and subsequent lines) Preliminary estimation of possible effect of the drug, added to chemotherapy, on tumor growth.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 51
• Est. completion date: January 2016
• Est. primary completion date: December 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

General criteria for the inclusion of patients with non-small cell lung cancer (NSCLC) and ovarian cancer (OC):

1. Signed patient's information sheet and informed consent form to participate in the study

2. Age 18 and older

3. The value of left ventricular ejection fraction, as determined by echocardiography data, more than 50%

4. Patient's ability to carry out visits and study procedures and to comply with the protocol

5. Requirements to laboratory parameters determined below:

Complete blood count: Absolute neutrophil count:

Platelets:

Haemoglobin: = 1500/mm3 (1.5 x 109 cells/l)

• 100 000/mm3 (100 x 109 cells/l)

• 9.0 g/dl

Liver function: Total bilirubin:

aspartate aminotransferase (AST) and alanine aminotransferase (ALT): = 1.5-fold of the upper limit of normal (ULN)

= 2.5--fold of ULN or = 5.0-fold of ULN in case of metastases in liver Kidney function: GRF (by Cockcroft-Gault equation) > 50 ml/min

6. The expected survival time not less than 6 months

7. Women and men of childbearing potential (not sterile or in menopause less than 2 years) must be practicing an effective method of birth control starting from the screening period, during the study and 6 months after the last administration of the investigational product. Effective methods include use a condom or diaphragm (barrier method) with spermicide.

8. Functional status of the patient according to the ECOG 0 - 2 Special criteria for patients with NSCLC

9. Histologically or cytologically confirmed diagnosis of non-resectable non-small-cell lung cancer

10. The progression of lung cancer after a maximum of one line of systemic anticancer therapy (adjuvant chemotherapy will be considered first-line therapy if the time from the moment of its completion until disease progression was less than 6 months)

11. No history of treatment with Gemcitabine if the patient is planned for inclusion in the group of chemotherapy with Cisplatin and Gemcitabine, or Paclitaxel if the patient is planned for inclusion in the group of Carboplatin and Paclitaxel.

12. Vital capacity of lung by spirometry data is more than 50% of normal at screening

Special inclusion criteria for patients with ovarian cancer

13. Histologically confirmed diagnosis of ovarian cancer.

14. Progression after no more than three modes of anticancer drug therapy for ovarian cancer.

Exclusion Criteria:

1. Indications for X-ray therapy or chemoradiation therapy at the time of inclusion, regardless of the treated area;

2. Presence of clinical and/or radiological signs of metastases in the brain and meningeal structures (CNS);

3. Previous therapy with HDAC inhibitors

4. Any contraindications to the chemotherapy with Gemcitabine + Cisplatin or Paclitaxel + Carboplatin (in patients with lung cancer); contraindications to chemotherapy according to the standard chemotherapy combination scheme Paclitaxel + Carboplatin (in female patients with ovarian cancer);

5. Any contraindications to administration of glucocorticosteroids, antihistamine drugs, serotonin 5-HT3 receptor antagonists, aprepitant;

6. Any contraindications to forced rehydration and/or administration of forced diuresis (in case of lung cancer);

7. Conditions that require continuous use of oral anticoagulants, or clinically significant changes in blood coagulation parameters at screening (INR > 1.5, aPTT> 1.5 ? ULN)

8. Conditions that require admission of prohibited drugs, or impossibility to replace those with allowed drugs in the study

9. Current infection or other systemic conditions constituting a contraindication to the intended chemotherapy;

10. Diseases of the digestive system which may infringe absorption of the investigational product (Crohn's disease, nonspecific ulcerative colitis, irritable bowel syndrome)

11. Clinically significant cardiovascular diseases including:

• Myocardial infarction within 12 months before screening

• Unstable angina within 12 months before screening

• Congestive heart failure Class III or IV according to the New York Heart Association criteria (NYHA)

• Clinically significant ventricular arrhythmia including ventricular tachycardia, ventricular fibrillation, history of cardiac arrest, atrioventricular block (Mobitz II or III), use of cardiostimulator

• QTc interval > 450 ms in men or 470 ms in women (ECG) (calculated according to Fredericia formula), or a diagnosis of long QT syndrome

• Hypotension (systolic blood pressure < 86 mm Hg or bradycardia with a heart rate of < 50 beats per minute (ECG) except when caused by medications (e.g. beta-blockers).

• Uncontrolled arterial hypertension (systolic arterial pressure > 170 millimeters of mercury or diastolic blood pressure > 105 millimeters of mercury)

12. Pregnancy and lactation

13. Presence of HIV antibodies, Hepatitis ? and ? antibodies

14. Drug or alcohol abuse at the moment of screening or in the past which according to the opinion of the Investigator makes the patient unsuitable for participation in the study

15. Significant allergic reactions in medical history

16. Participation in other clinical studies or administration of test drugs during 30 days before beginning of the study or persisting side effect of any of the test drugs;

17. Toxic effects of previous treatments or complications after surgical treatments that did not resolve to grades 1 and/or 0 (according to the CTCAE scale).

18. Patient not willing to participate in the study or unable to understand or follow the protocol instructions.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Epithelial Ovarian Cancer
• Neoplasms, Glandular and Epithelial
• Non-small Cell Lung Cancer
• Ovarian Neoplasms

Intervention

Drug:
• Quisinostat

• Paclitaxel

• Carboplatin

• Gemcitabine

• Cisplatin

Locations

Country	Name	City	State
Russian Federation	Russian Oncological Research Center n.a. N. N. Blokhin RAMS	Moscow
Russian Federation	State Budgetary Healthcare Institution of Stavropol Territory "Pyatigorsk oncology dispensary"	Pyatigorsk
Russian Federation	BioEq LLC	Saint-Petersburg
Russian Federation	Saint-Peterburg State Budgetary healthcare Institution "City Clinical Oncology Dispensary"	Saint-Petersburg
Russian Federation	State Budget Institution of healthcare "Saint-Petersburg clinical research and practical centre of specialized medical aid (oncology)"	Saint-Petersburg
Russian Federation	State Healthcare Institution of Yaroslavl region "Regional Clinical oncology hospital"	Yaroslavl

Sponsors (2)

Lead Sponsor	Collaborator
NewVac LLC	Janssen Pharmaceutica N.V., Belgium

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Peak Plasma Concentration (Cmax) of Quisinostat		Day 1, Day 7	No
Other	Area under the Quisinostat plasma concentration versus time curve (AUC)		Day 1, Day 7	No
Primary	safety and tolerability of Quisinostat based on number of patients with treatment -related AEs assessed by CTCAE v4.0, number of patients with abnormal laboratory values and instrumental tests (ECG) that are related to treatment		22 weeks	Yes